>>Imetelstat has not be promulgated as a cancer cure particularly as a single agent<<
Actually there was a time when Okarma did use the word "cure" and it was hoped the drug would be efficacious as a single agent. When both hopes failed, the goalposts were widened and moved - par for the course with Geron.
To my knowledge - and if I'm wrong, somebody here will surely point it out in a millisecond or two - there has never been a successful cancer drug which did not show some clear signs of efficacy first as a single agent. And that includes Avastin, although Avastin turned out to be much more efficacious in apppropriate combinations.
Imetelstat has shown no signs of efficacy as a single agent after almost 5 years and numerous clinical trials applying it to a wide variety of indications. The drug has turned out to be quite toxic, whereas many predicted it would not be until one reached doses much higher than needed for efficacy. I don't rule out the possibility that imetelstat may eventually be shown to work, but the chances are quite slim at this point and the suggestion that some other drug not working is good news for Geron is like saying in September 2008 that some banks failing is good news for Lehman Brothers.
BTW - telomerase inhibition demonstrates biological activity, but NOT clinical efficacy.
>>Check out the current abstracts at AACR suggesting significant activity across broad cancer types.<<
Every drug that makes it into the clinic first shows activity against cancer cells in test tubes and in mice. Yet >90% fail.
>>I am content to sit back, be patient, watch the scientists do their work and be amazed.<<
And lose money. (Sorry - couldn't resist!) Geron has always done great and exciting science. But after 20 years they are still not even close to becoming a business, let alone a profitable one. Good luck, though.
micro
Market Data 
Markets 
AI
